Martinsried/Munich – Medigene AG announced that researchers of the Company will present a poster at the 2019 American Association for Cancer Research Annual Meeting. They will present innovative meth-ods for the evaluation of efficacy and toxicity of TCRs (T cell receptors) during the meeting that is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta, USA.
The authors, scientists at Medigene, describe the use of 3D spheroids generated from tumor cell lines for assessment of TCR efficacy or healthy cells for evaluation of potential TCR-derived toxicity. Spheroids were co-cultured with TCR-transduced T cells and killing of spheroids was analyzed in real-time using a live cell imaging system.
TCR-transduced T cells showed efficient killing of tumor cell spheroids, confirming the results generated previously in a 2D system. Furthermore, 3D spheroids generated from healthy cells (e.g. normal human lung fibroblasts) were not killed via TCR-transduced T cells.
Usage of this 3D spheroid model for the evaluation of toxicity is a major building block for the effective development of highly innovative TCR-T cell therapy.
The full abstract of the poster with the title “In vitro evaluation of TCR efficacy and toxicity using 3D spheroid models” is now available under this link: www.abstractsonline.com/pp8/ # !/6812/presentation/2604 or http://tiny.cc/anwm3y
The poster with the abstract number 2303 will become available after the presentation at AACR on 1 April 2019 on Medigene’s company website: https://medigene.com/technologies/publications/.
About Medigene’s TCR-Ts: Medigene’s first TCR-T candidate, MDG1011, is in a Phase I/II clinical trial for various blood cancer indications started in 2018. The TCR-T technology aims at arming the patient’s own T cells with tumor-specific T cell receptors. The receptor-modified T cells are then able to detect and efficiently kill tumor cells. This immunotherapy approach attempts to overcome the patient’s tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient’s T cells outside the body (ex vivo). TCR-T therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR-T) therapy.
Medigene is establishing a pipeline of recombinant T cell receptors and has a collaboration with bluebird bio, Inc. for the development of six TCR-Ts.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell receptor-modified T cells (TCR-Ts) and has projects currently in preclinical and clinical development.
For more information, please visit https://medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01